Chiusura precedente | 3,0550 |
Aperto | 0,0000 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 400 |
Capitalizzazione | 2,174M |
Beta (5 anni mensile) | 0,64 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,5190 |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Believe the Board Needs to be Held Accountable for its Poor Judgment and Value-Destructive Initiatives Reiterate their Concern that the Board is Not Acting in the Best Interest of Stockholders Believe Immediate Action Must be Taken to Prevent the Further Destruction of Value TORONTO and SAN FRANCISCO, July 17, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 14.8% of th
Emphasizes the Board’s Failure to Adequately Consider the Superior Acquisition Proposal Presented by Anson Funds and Cable Car Capital Believes the Misguided Transaction with Infinity Pharmaceuticals Will Continue to Destroy Stockholder Value Have Voted Against the Proposed Combination ahead of the Upcoming Special Meeting Scheduled for July 14, 2023 TORONTO and SAN FRANCISCO, June 27, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson,
TORONTO and SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 14.8% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”; NasdaqCM: MEIP), today issued the following statement in response to the rejection by the Company’s board of directors (the “Board”) of our proposal to acquire all outstanding shares of MEIP not already